Atlas Trials

Investigating the Safety and Efficacy of Rituximab and Pembrolizumab in Relapsed/Refractory Waldenström's Macroglobulinaemia

Clinical trial NCT03630042 · COMPLETED

Trial details

NCT number
NCT03630042
Sponsor
University College, London
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Waldenstrom Macroglobulinemia
Start date
2019-09-06
Primary completion
2021-09-21
Enrollment
17

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.